Today's Date
Daratumumab and Belatacept for Desensitization
(
ATTAIN
)
ITN Protocol #:
ITN090ST
Branded Name:
ATTAIN
ClinicalTrials.Gov ID:
NCT04827979Treatment Protocol #:
Therapeutic Area:
Transplantation
Current Status:
Enrollment
Summary:
A Mechanistically Driven Therapy to Desensitize >98.0% cPRA Patients: Depletion of Plasma Cells With Anti-CD38 and Prevention of B Cell Activation With Costimulation Blockade
Clinical Operations Associate Director
Clinical Operations Manager
ITN Biologist
ITN Clinical Trial Physician
NIAID Project Manager
NIAID Regulator Officer
Rho Data Manager
Rho Scientist
PPD Lead Monitor
Study Personnel:
